23 May 2025 - AstraZeneca and Daiichi Sankyo are pleased to announce that Canada's Drug Agency has issued a time-limited reimbursement recommendation – the first in gastric cancer – for Enhertu (trastuzumab deruxtecan) based on the unmet need of adult patients with unresectable, locally advanced or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

Additionally, the pan-Canadian Pharmaceutical Alliance, AstraZeneca, and Daiichi Sankyo have recently signed a letter of intent through the recently introduced Temporary Access Process. This step, alongside the time limited reimbursement processes, paves the way for jurisdictional reimbursement.

Read Financial Times article